Atara Biotherapeutics (ATRA) Competitors

Atara Biotherapeutics (NASDAQ:ATRA) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Which has more volatility and risk, ATRA or IPHA?

Atara Biotherapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.

Do analysts rate ATRA or IPHA?

Atara Biotherapeutics presently has a consensus target price of $17.75, indicating a potential upside of 157.99%. Innate Pharma has a consensus target price of $11.50, indicating a potential upside of 483.76%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Innate Pharma is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Innate Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Which has better earnings & valuation, ATRA or IPHA?

Innate Pharma has lower revenue, but higher earnings than Atara Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$128.94M	0.31	-$276.13M	-$12.97	-0.53
Innate Pharma	$24.85M	6.65	-$8.19M	N/A	N/A

Does the media refer more to ATRA or IPHA?

In the previous week, Innate Pharma had 6 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 7 mentions for Innate Pharma and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.62 beat Innate Pharma's score of 0.50 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
Innate Pharma	Positive

Do institutionals and insiders believe in ATRA or IPHA?

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 3.7% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor ATRA or IPHA?

Atara Biotherapeutics received 391 more outperform votes than Innate Pharma when rated by MarketBeat users. Likewise, 67.33% of users gave Atara Biotherapeutics an outperform vote while only 58.97% of users gave Innate Pharma an outperform vote.

Company	Underperform	Outperform
Atara Biotherapeutics	Outperform Votes 437 67.33%	Underperform Votes 212 32.67%
Innate Pharma	Outperform Votes 46 58.97%	Underperform Votes 32 41.03%

Is ATRA or IPHA more profitable?

Innate Pharma has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-132.58%	N/A	-90.16%
Innate Pharma	N/A	N/A	N/A

Summary

Innate Pharma beats Atara Biotherapeutics on 8 of the 15 factors compared between the two stocks.